Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. by Rizzoli, R, Reginster, J, Boonen, S, Bréart, G, Diez-Perez, A, Felsenberg, D, Kaufman, J, Kanis, J, Cooper, C

“…Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet. The selective estrogen receptor modulators are associated with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke. …”

Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the... by Cooper, C, Reginster, J, Cortet, B, Diaz-Curiel, M, Lorenc, R, Kanis, J, Rizzoli, R

“…METHODS: We reviewed the efficacy and safety of calcium and vitamin D, the selective estrogen receptor modulators (SERMs), the bisphosphonates, denosumab, and strontium ranelate in studies of 3 years or longer. …”